Lung vascular volumes in cystic fibrosis patients before and after Elexacaftor-Tezacaftor-Ivacaftor (ETI) therapy

<bold>Rationale:</bold> Low attenuation regions (LAR) in CF lung disease reflects trapped air and hypoperfusion secondary to hypoxic pulmonary vasoconstriction. <bold>Aim:</bold> To assess changes in LAR and lung arterial and venous blood volumes before and after introduction of ETI. <bold>Hypothesis:</bold> ETI results in a reduction of LAR, higher small (0.2-1mm) arterial and venous volumes and a reduction in upstream (>2mm) arterial volume. <bold>Methods:</bold> 9 CF patients, age 35(26-39) years, (M2,F7) underwent broncho alveolar lavage and an ins- and expiratory chest CT scan before, and on ETI therapy 1.5 years later. CTs were automatically analysed (LungQ V.3.0.1, Thirona, Nijmegen, NL). LungQ-VERA assesses LAR (%total lung volume). LungQ-AVX assesses arterial and venous blood volumes (%total lung blood volume) in bins of: 0.2-1, 1-2, >2 mm. <bold>Results:</bold> On ETI, LAR reduced by 42% (23.94(6.30-41.36)% to 13.95(1.87-23.31)% (p=0.028)). Blood volumes (Table). <bold>Conclusions:</bold> ETI therapy results in: reductions in LAR and higher venous blood volumes. The trend in higher small (0.2-1mm) arterial volume and reduced upstream (>2 mm) arterial volume suggest improved arterial perfusion and a reduction in pulmonary arterial pressure. <table-wrap><object-id>erj;64/suppl_68/PA5257/T1</object-id><object-id>T1</object-id><object-id>t1</object-id><table><colgroup><col></col><col></col><col></col><col></col></colgroup><tbody><tr><td>Variable</td><td> Pre-ETI, Blood volume (%) Median (SD) </td><td> On-ETI, Blood volume (%) Median (SD) </td><td> Statistics, P-value </td></tr><tr><td>Arteries 0.2-1 mm</td><td>4.97 (1.364)</td><td>7.07 (1.58)</td><td>U = 21, p = 0.094</td></tr><tr><td>Arteries 1-2 mm</td><td>11.68 (2.45)</td><td>9.73 (1.08)</td><td>U = 55, p = 0.222</td></tr><tr><td>Arteries >2 mm</td><td>42.11 (7.76)</td><td>37.38 (4.56)</td><td>U = 62, p = 0.063</td></tr><tr><td>Veins 0.2-1 mm</td><td>3.04 (0.88)</td><td>4.47 (0.84)</td><td>U = 18, p = 0.040</td></tr><tr><td>Veins 1-2 mm</td><td>6.84 (1.40)</td><td>8.17 (1.07)</td><td>U = 13, p = 0.014</td></tr><tr><td>Veins >2 mm</td><td>28.91 (5.19)</td><td>33.62 (3.73)</td><td>U = 18, p = 0.040</td></tr></tbody></table></table-wrap>

Authors

Institutions

Publication Details

Published
2024-09-14
DOI
https://doi.org/10.1183/13993003.congress-2024.pa5257
Primary Topic
Cystic Fibrosis Research Advances
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Lung vascular volumes in cystic fibrosis patients before and after Elexacaftor-Tezacaftor-Ivacaftor (ETI) therapy

David A. Stoltz, Tahuanty Peña, Pradeep K. Singh, S. Durfey et al.
Cystic Fibrosis Research Advances
article

Lung vascular volumes in cystic fibrosis patients before and after Elexacaftor-Tezacaftor-Ivacaftor (ETI) therapy

David A. Stoltz, Tahuanty Peña, Pradeep K. Singh, S. Durfey, Siddhartha G. Kapnadak, Ieva Aliukonyte, P. Makani, Harm Tiddens, M. Teresi
article en

Abstract

<bold>Rationale:</bold> Low attenuation regions (LAR) in CF lung disease reflects trapped air and hypoperfusion secondary to hypoxic pulmonary vasoconstriction. <bold>Aim:</bold> To assess changes in LAR and lung arterial and venous blood volumes before and after introduction of ETI. <bold>Hypothesis:</bold> ETI results in a reduction of LAR, higher small (0.2-1mm) arterial and venous volumes and a reduction in upstream (>2mm) arterial volume. <bold>Methods:</bold> 9 CF patients, age 35(26-39) years, (M2,F7) underwent broncho alveolar lavage and an ins- and expiratory chest CT scan before, and on ETI therapy 1.5 years later. CTs were automatically analysed (LungQ V.3.0.1, Thirona, Nijmegen, NL). LungQ-VERA assesses LAR (%total lung volume). LungQ-AVX assesses arterial and venous blood volumes (%total lung blood volume) in bins of: 0.2-1, 1-2, >2 mm. <bold>Results:</bold> On ETI, LAR reduced by 42% (23.94(6.30-41.36)% to 13.95(1.87-23.31)% (p=0.028)). Blood volumes (Table). <bold>Conclusions:</bold> ETI therapy results in: reductions in LAR and higher venous blood volumes. The trend in higher small (0.2-1mm) arterial volume and reduced upstream (>2 mm) arterial volume suggest improved arterial perfusion and a reduction in pulmonary arterial pressure. <table-wrap><object-id>erj;64/suppl_68/PA5257/T1</object-id><object-id>T1</object-id><object-id>t1</object-id><table><colgroup><col></col><col></col><col></col><col></col></colgroup><tbody><tr><td>Variable</td><td> Pre-ETI, Blood volume (%) Median (SD) </td><td> On-ETI, Blood volume (%) Median (SD) </td><td> Statistics, P-value </td></tr><tr><td>Arteries 0.2-1 mm</td><td>4.97 (1.364)</td><td>7.07 (1.58)</td><td>U = 21, p = 0.094</td></tr><tr><td>Arteries 1-2 mm</td><td>11.68 (2.45)</td><td>9.73 (1.08)</td><td>U = 55, p = 0.222</td></tr><tr><td>Arteries >2 mm</td><td>42.11 (7.76)</td><td>37.38 (4.56)</td><td>U = 62, p = 0.063</td></tr><tr><td>Veins 0.2-1 mm</td><td>3.04 (0.88)</td><td>4.47 (0.84)</td><td>U = 18, p = 0.040</td></tr><tr><td>Veins 1-2 mm</td><td>6.84 (1.40)</td><td>8.17 (1.07)</td><td>U = 13, p = 0.014</td></tr><tr><td>Veins >2 mm</td><td>28.91 (5.19)</td><td>33.62 (3.73)</td><td>U = 18, p = 0.040</td></tr></tbody></table></table-wrap>

University of Iowa (US), University of Washington (US), Erasmus MC - Sophia Children’s Hospital (NL)
Good health and well-being
Openalex Percentile: Top 64%
Cystic Fibrosis Research Advances
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.